Dr. Diem Nguyen,  the CEO of Xalud Therapeutics, talks about Xalud’s work to reduce the inflammation that drives pain. It’s now in human clinical trials.

SOTIO, for example – an international biotech originating from the Czech Republic – focuses on immuno-oncology and developing innovative methods for treating cancer. The company has been conducting multiple Phase I to III clinical trials, and uniquely uses four distinct technological platforms, which each include multiple promising drug candidates.

Yochi Slonim, M.Sc., co-founder and CEO of Anima Biotech, explained the rationale for building a platform technology company in Israel.

Our plan to achieve sustainability as a business practice in the coming years lies within Calliditas’ strategy to execute on our vision to efficiently expand, develop, and market our pipeline of innovative medicines targeting rare diseases that have the potential to improve the lives of patients with

At Xalud, we’re developing a non-viral plasmid DNA platform that has the potential to change the paradigm in chronic inflammatory diseases by creating a gene therapy for the masses and not just for rare diseases. We have a pipeline with broad potential for our proprietary platform, including several programs in development, and we look forward to being part of this new wave in gene therapy.

But in 2019, he walked away from all of that to become the founder and CEO of Alto Neuroscience, which the company said is “pioneering an approach to psychiatric drug development which matches the right patient with the right Alto drug based on AI-derived brain biomarkers.”

Teclison has developed platform technology that chokes off tumors and activates the immune system against the cancer.

That’s why Yoav Kimchy, Founder and CTO of Check-Cap, launched the company in 2005 with the goal of creating a technology that could make colorectal screenings easier and less invasive for patients.